Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 620.32M P/E - EPS this Y -9.00% Ern Qtrly Grth -
Income -162.1M Forward P/E -3.39 EPS next Y 38.10% 50D Avg Chg -2.00%
Sales 374k PEG 0.01 EPS past 5Y - 200D Avg Chg -15.00%
Dividend N/A Price/Book N/A EPS next 5Y -134.00% 52W High Chg -49.00%
Recommedations 2.70 Quick Ratio 0.83 Shares Outstanding 152.38M 52W Low Chg 13.00%
Insider Own 5.44% ROA -27.10% Shares Float 120.20M Beta 2.01
Inst Own 45.40% ROE - Shares Shorted/Prior 17.22M/16.75M Price 4.85
Gross Margin - Profit Margin - Avg. Volume 2,589,375 Target Price 3.34
Oper. Margin -42,211.23% Earnings Date Oct 31 Volume 1,415,031 Change 0.41%
About Seres Therapeutics, Inc.

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

Seres Therapeutics, Inc. News
11/22/24 Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
11/15/24 Seres Therapeutics Third Quarter 2024 Earnings: US$0.33 loss per share (vs US$0.37 loss in 3Q 2023)
11/14/24 Seres Therapeutics Inc (MCRB) Q3 2024 Earnings Call Highlights: Strategic Moves and Clinical ...
11/13/24 Seres Therapeutics: Q3 Earnings Snapshot
11/13/24 Seres Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
11/06/24 Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024
10/08/24 Institutions along with retail investors who hold considerable shares inSeres Therapeutics, Inc. (NASDAQ:MCRB) come under pressure; lose 12% of holdings value
09/30/24 Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A
09/26/24 Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30
09/13/24 Seres Therapeutics to Participate in Cantor 2024 Global Healthcare Conference
09/12/24 Seres Therapeutics Reports SER-155 Phase 1b Placebo-Controlled Cohort 2 Study Safety and Clinical Results in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT)
09/04/24 After Plunging -22.45% in 4 Weeks, Here's Why the Trend Might Reverse for Seres Therapeutics (MCRB)
08/15/24 Bears are Losing Control Over Seres Therapeutics (MCRB), Here's Why It's a 'Buy' Now
08/14/24 Q2 2024 Seres Therapeutics Inc Earnings Call
08/13/24 Seres Therapeutics: Q2 Earnings Snapshot
08/13/24 Seres Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
08/06/24 Seres Therapeutics to Announce Second Quarter 2024 Financial Results and Business Update on August 13, 2024
08/06/24 Seres Therapeutics Announces Signing of VOWST™ Asset Purchase Agreement with Nestlé Health Science
07/19/24 Even after rising 29% this past week, Seres Therapeutics (NASDAQ:MCRB) shareholders are still down 84% over the past three years
06/07/24 Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
MCRB Chatroom

User Image BankingWithLiz Posted - 3 hours ago

$ABVE Top squeeze candidate in to monday ! low float uptrending! $GEVO bio swings $MCRB Long hold $ICCC adding

User Image Hydrogem Posted - 9 hours ago

$MCRB If previous rumors are to be believed, it is not Nestles interest that is in question. It is Seres’ greed and delusion that they can survive on their own. Whether it is management or Flagship or a combination, they supposedly turned down offers of $6-$6.50 previously. Why would they now accept $3-5 a share? Not a rhetorical question.

User Image Fairvalue10 Posted - 11 hours ago

$MCRB Is NHS also participating ?

User Image Fairvalue10 Posted - 17 hours ago

$MCRB Sept 12 th Seres engaged with the FDA to seek Breakthrough Therapy For SER 155. It could be the catalyst.

User Image Fairvalue10 Posted - 17 hours ago

$MCRB Best Case Analysis: If Seres Therapeutics has 170 million shares outstanding and Nestlé already owns 15%, the calculation is as follows: Cost to acquire the remaining 85% at $4 per shares : 144.5 million shares X 4 = 578 millions USD. If Nestlé were to acquire the entire company, it would need to pay approximately $578 million. This approach could prove more cost-effective than paying +/- $500 millions with potential milestone payments for Vowst, a low-margin treatment that is unlikely to deliver significant profitability. By acquiring the full company, Nestlé would not only secure Vowst but also gain control of Seres’ entire pipeline and intellectual property, potentially unlocking greater long-term strategic and financial value.

User Image Solfer Posted - 19 hours ago

$MCRB Sorry to throw water on the fire, but it's not a meeting, it's the annual Piper Sandler conference. Seres participated last year too, so it's nothing unusual. Need to keep it real...

User Image KABStockOptionCommunity Posted - 23 hours ago

$MCRB

User Image WombatAstronaut Posted - 1 day ago

$MCRB Good week overall - imo this was the critical level to maintain, and we held it. I'll keep it short, but the other indicators I'm watching here still look good, and price has been getting bounced between key SMAs in a tightening channel. I could see that continuing in this range until we wind up to break out (hopefully up). Next key level is 0.84 to close above on the daily, which would introduce a significant support level we've rejected on the 55 SMA.

User Image lisaparsons Posted - 1 day ago

$MCRB patience. But please don’t reverse split. Please management blessings

User Image PappyVan Posted - 1 day ago

$MCRB Here you go Wayne…

User Image LionNoRichy Posted - 1 day ago

$MCRB we got a green week, cheers everyone

User Image Freshsuits Posted - 1 day ago

$MCRB 40% this week. Have a good weekend longs

User Image PappyVan Posted - 1 day ago

$MCRB Green Day!!! 💚🍀

User Image Lynne45 Posted - 1 day ago

$MCRB 💚

User Image Electhim Posted - 1 day ago

$MCRB. Might hit $.80 after all. 🤷

User Image Freshsuits Posted - 1 day ago

$MCRB Anything over 78 is very bullish.

User Image GringotsAG Posted - 1 day ago

$MCRB power V recovery. Interest is still high here. need to gain some hands on what they said at the conference. Keep digging through Nestles Academy and some shady sites.. they have plenty of material up there. Microbiome is top tier to NH.

User Image jow18 Posted - 1 day ago

$MCRB algo vs algo. Nothing to see here..

User Image Electhim Posted - 1 day ago

$MCRB It makes no sense to have a meeting with Piper unless you have some substantial news like a partnership. We no longer have a revenue producing drug Maybe this is lining up for something good 😌

User Image Thepark88 Posted - 1 day ago

$MCRB I’ve asked them for a power hour

User Image Mikelonggggggggg Posted - 1 day ago

$MCRB I grow increasingly impatient as each day goes by that I look at my unrealized losses here...

User Image Freshsuits Posted - 1 day ago

$MCRB I’ll wait for one of the shorts to explain to me how they’re going to operate on their own with 100 employees, down from 400 with VOWST. Still waiting for a CTO replacement. Just sell the company already. Hold my beer.

User Image TotalChamp Posted - 1 day ago

$MCRB nice little skip there. Sorry, I don’t have anything more beneficial to say. I’m just a long. If my words don’t help atleast my money will.

User Image Electhim Posted - 1 day ago

$MCRB moves up easily when MM takes his foot off the brakes

User Image Freshsuits Posted - 1 day ago

$MCRB Close over 80 would be lovely

User Image Bulltrader988 Posted - 1 day ago

$MCRB "will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 4:30 p.m. ET. " Eventually we hear something about SER-155? https://ir.serestherapeutics.com/news-releases/news-release-details/seres-therapeutics-participate-piper-sandler-healthcare

User Image Electhim Posted - 1 day ago

$MCRB talk about volume drying up quickly 🤨

User Image steven1x Posted - 1 day ago

$MCRB if missed https://event.webcasts.com/starthere.jsp?ei=1698833&tp_key=e0d0a7270b

User Image coreholder Posted - 1 day ago

$MCRB I am happy to patiently wait out the shenanigans….BO or partnership inbound at some point

User Image Electhim Posted - 1 day ago

$MCRB shorts are relentless. They just won’t let us run.

Analyst Ratings
Canaccord Genuity Buy Sep 13, 24
Canaccord Genuity Buy Aug 14, 24
Chardan Capital Buy Aug 14, 24
Oppenheimer Perform Jun 7, 24
Canaccord Genuity Buy Jun 7, 24
Oppenheimer Outperform May 9, 24
Chardan Capital Buy May 8, 24
Oppenheimer Outperform Mar 6, 24
Chardan Capital Buy Mar 6, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Cloghessy Paula See Remarks See Remarks Oct 27 Option 0 9,418 48,588 10/31/23
Cloghessy Paula See Remarks See Remarks Oct 27 Sell 1.35 2,904 3,920 45,684 10/31/23
Shaff Eric D. CEO and President CEO and President Oct 27 Sell 1.35 8,552 11,545 115,620 10/31/23
Shaff Eric D. CEO and President CEO and President Oct 27 Option 0 27,838 124,172 10/31/23
Young Teresa L. See Remarks See Remarks Oct 27 Sell 1.35 2,907 3,924 8,454 10/31/23
Young Teresa L. See Remarks See Remarks Oct 27 Option 0 11,361 11,361 10/31/23
Arkowitz David Chief Financial Offi.. Chief Financial Officer Oct 27 Sell 1.35 4,066 5,489 175,756 10/31/23
Arkowitz David Chief Financial Offi.. Chief Financial Officer Oct 27 Option 0 13,209 179,822 10/31/23
DesRosier Thomas Chief Legal Officer.. Chief Legal Officer and EVP Oct 27 Option 0 13,501 118,047 10/31/23
DesRosier Thomas Chief Legal Officer.. Chief Legal Officer and EVP Oct 27 Sell 1.35 4,156 5,611 113,891 10/31/23
Ege David S. See Remarks See Remarks Oct 27 Sell 1.35 4,066 5,489 66,991 10/31/23
Ege David S. See Remarks See Remarks Oct 27 Option 0 11,361 71,057 10/31/23
von Moltke Lisa See Remarks See Remarks Oct 27 Sell 1.35 4,232 5,713 9,513 10/31/23
von Moltke Lisa See Remarks See Remarks Oct 27 Option 0 13,745 13,745 10/31/23
Henn Matthew R. See Remarks See Remarks Oct 27 Sell 1.35 3,886 5,246 56,356 10/31/23
Henn Matthew R. See Remarks See Remarks Oct 27 Option 0 12,623 60,242 10/31/23
Ege David S. See Remarks See Remarks Apr 27 Sell 5.19 7,038 36,527 59,696 05/01/23
Ege David S. See Remarks See Remarks Oct 27 Sell 7.93 5,012 39,745 46,734 10/31/22
Nutritional Health LTP Fund Ge... 10% Owner 10% Owner Jul 05 Buy 3.15 8,738,243 27,525,465 5,825,495 07/07/22